Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.48 |
| ▸ | MMP9 | P14780 | 9/20 | 0.48 |
| ▸ | MMP3 | P08254 | 7/20 | 0.48 |
| ▸ | MMP1 | P03956 | 6/20 | 0.48 |
| ▸ | MMP8 | P22894 | 5/20 | 0.48 |
| ▸ | MMP14 | P50281 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | Q9HBH1 | 1/20 | 0.40 | |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | FCER2 | P06734 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.36 |
| ▸ | MMP7 | P09237 | 2/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9714184 | 0.84 | DPP4 (0.40) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL9714104 | 0.80 | DPP4 (0.36) | DPP4 | |
| SCHEMBL9714153 | 0.75 | MMP1 (0.49) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL14068125 | 0.73 | MMP2 (0.59) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL9714049 | 0.72 | MMP2 (0.46) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL9714087 | 0.71 | MMP1 (0.41) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL8890070 | 0.70 | MMP2 (0.54) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL7426952 | 0.70 | MMP2 (0.54) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL7073422 | 0.69 | MMP2 (0.50) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL8601655 | 0.68 | MMP2 (0.65) | MMP2MMP9MMP3MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP9 1/4885MMP3 3/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP9 1/4885MMP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.